Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Unveiling the Binding between the Armadillo-Repeat Domain of Plakophilin 1 and the Intrinsically Disordered Transcriptional Repressor RYBP

  • Araujo-Abad, Salomé
  • Rizzuti, Bruno
  • Vidal, Miguel
  • Abian, Olga
  • Fárez-Vidal, María Esther
  • Velázquez-Campoy, Adrián
  • de Juan Romero, Camino
  • Neira, José L.
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., Plakophilin 1 (PKP1), a member of the p120ctn subfamily of the armadillo (ARM)-repeat-containing proteins, is an important structural component of cell–cell adhesion scaffolds although it can also be ubiquitously found in the cytoplasm and the nucleus. RYBP (RING 1A and YY1 binding protein) is a multifunctional intrinsically disordered protein (IDP) best described as a transcriptional regulator. Both proteins are involved in the development and metastasis of several types of tumors. We studied the binding of the armadillo domain of PKP1 (ARM-PKP1) with RYBP by using in cellulo methods, namely immunofluorescence (IF) and proximity ligation assay (PLA), and in vitro biophysical techniques, namely fluorescence, far-ultraviolet (far-UV) circular dichroism (CD), and isothermal titration calorimetry (ITC). We also characterized the binding of the two proteins by using in silico experiments. Our results showed that there was binding in tumor and non-tumoral cell lines. Binding in vitro between the two proteins was also monitored and found to occur with a dissociation constant in the low micromolar range (~10 μM). Finally, in silico experiments provided additional information on the possible structure of the binding complex, especially on the binding ARM-PKP1 hot-spot. Our findings suggest that RYBP might be a rescuer of the high expression of PKP1 in tumors, where it could decrease the epithelial–mesenchymal transition in some cancer cells., This research was funded by the Spanish Ministry of Economy and Competitiveness and European ERDF Funds (MCIU/AEI/Feder, EU), grant numbers PID2021-127296OB-I00 to A.V.-C. and CP19/00095 to C.d.J.R.; Fondo de Investigaciones Sanitarias from Instituto de Salud Carlos III and European Union (ERDF/ESF, “Investing in your future”), grant numbers PI21/00394 to O.A. and PI22/00824 to C.d.J.R.; PAIDI program, Group BIO309; Junta de Andalucía and Fondo de Investigaciones Sanitarias from Instituto de Salud Carlos III, grant number PI10/00198, to M.E.F.-V.; Diputación General de Aragón, grant numbers E45-20R to A.V.-C. and B25-20R to O.A.; and Consellería de Innovación, Universidades, Ciencia y Sociedad Digital (Comunidad Valenciana), grant number CIAICO 2021/0135 to J.L.N. and C.d.J.R., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Intrinsically disordered chromatin protein NUPR1 binds to the enzyme PADI4

  • Araujo-Abad, S.
  • Neira, J. L.
  • Rizzuti, B.
  • García-Morales, P.
  • Juan Romero, C. de
  • Santofimia-Castaño, P.
  • Iovanna, J.
The nuclear protein 1 (NUPR1) is an intrinsically disordered protein involved in stress-mediated cellular conditions. Its paralogue nuclear protein 1-like (NUPR1L) is p53-regulated, and its expression down-regulates that of the NUPR1 gene. Peptidyl-arginine deiminase 4 (PADI4) is an isoform of a family of enzymes catalyzing arginine to citrulline conversion; it is also involved in stress-mediated cellular conditions. We characterized the interaction between NUPR1 and PADI4 in vitro, in silico, and in cellulo. The interaction of NUPR1 and PADI4 occurred with a dissociation constant of 18 ± 6 μM. The binding region of NUPR1, mapped by NMR, was a hydrophobic polypeptide patch surrounding the key residue Ala33, as pinpointed by: (i) computational results; and, (ii) site-directed mutagenesis of residues of NUPR1. The association between PADI4 and wild-type NUPR1 was also assessed in cellulo by using proximity ligation assays (PLAs) and immunofluorescence (IF), and it occurred mainly in the nucleus. Moreover, binding between NUPR1L and PADI4 also occurred in vitro with an affinity similar to that of NUPR1. Molecular modelling provided information on the binding hot spot for PADI4. This is an example of a disordered partner of PADI4, whereas its other known interacting proteins are well-folded. Altogether, our results suggest that the NUPR1/PADI4 complex could have crucial functions in modulating DNA-repair, favoring metastasis, or facilitating citrullination of other proteins.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

The intrinsically disordered, epigenetic factor RYBP binds to the citrullinating enzyme PADI4 in cancer cells

  • Araujo-Abad, Salomé
  • Fuentes-Baile, María
  • Rizzuti, Bruno
  • Bazán, J. Fernando
  • Villamarin-Ortiz, Adrián
  • Saceda, Miguel
  • Fernández, Eduardo
  • Vidal, Miguel
  • Abian, Olga
  • Velázquez-Campoy, Adrián
  • Juan Romero, Camino de
  • Neira, José L.
RYBP (Ring1 and YY 1 binding protein) is a multifunctional, intrinsically disordered protein (IDP), best described as a transcriptional regulator. It exhibits a ubiquitin-binding functionality, binds to other transcription factors, and has a key role during embryonic development. RYBP, which folds upon binding to DNA, has a Zn-finger domain at its N-terminal region. By contrast, PADI4 is a well-folded protein and it is one the human isoforms of a family of enzymes implicated in the conversion of arginine to citrulline. As both proteins intervene in signaling pathways related to cancer development and are found in the same localizations within the cell, we hypothesized they may interact. We observed their association in the nucleus and cytosol in several cancer cell lines, by using immunofluorescence (IF) and proximity ligation assays (PLAs). Binding also occurred in vitro, as measured by isothermal titration calorimetry (ITC) and fluorescence, with a low micromolar affinity (~1 μM). AlphaFold2-multimer (AF2) results indicate that PADI4's catalytic domain interacts with the Arg53 of RYBP docking into its active site. As RYBP sensitizes cells to PARP (Poly (ADP-ribose) polymerase) inhibitors, we applied them in combination with an enzymatic inhibitor of PADI4 observing a change in cell proliferation, and the hampering of the interaction of both proteins. This study unveils for the first time the possible citrullination of an IDP, and suggests that this new interaction, whether it involves or not citrullination of RYBP, might have implications in cancer development and progression.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

The Citrullinating Enzyme PADI4 Binds to Lipids: Identification of New Target Interactions for Cancer Therapy

  • Araujo-Abad, Salomé
  • García-Peñarrubia, Borja
  • Giudici, A.Marcela
  • Neira, José L.
  • Rizzuti, Bruno
  • de Juan Romero, Camino
  • Poveda, José A.
Cancer cells need to implement and maintain molecular mechanisms relying on an energy trade-off between resistance and key functions to survive. Among them, changes in lipid metabolism are crucial. Phosphatidylserine (PS), phosphatidylcholine (PC) and phosphatidic acid (PA) are some of the lipids forming cell membranes and having key functions in lipid metabolism. PADI4 is an enzyme implicated in the conversion of arginine to citrulline (citrullination), that has been related with the development of several types of cancers. In this work, we report the lipid binding properties of PADI4. Such binding was assayed in vitro against zwitterionic (PC) and anionic (PA and PS) lipids, and it was monitored by several biophysical techniques. Furthermore, results in silico showed that the binding of PADI4 with PA, PC and PS occurred at the active site of the enzyme. This binding was confirmed in cellulo by using PS as the target lipid, employing immunofluorescence (IF) and proximity ligation assay (PLA) in different cancer cell lines. The use in cellulo of a specific enzymatic inhibitor of PADI4, GSK484, abolished the binding between PADI4 and PS in cancer cells, further indicating that their interaction occurred at the protein active site. Altogether, this work shows that PADI4 was capable of binding to lipids, and opens the venue to study the role that it could be playing in deimination processes and cancer development. Moreover, this study lays the foundation for developing novel cancer therapies from new perspectives, based on the interaction of lipids with citrullinating enzymes.